Long-Term Impact of Denosumab on Bone Disease in Patients with CKD.
Ken IseriMasahide MizobuchiRenaud WinzenriethLudovic HumbertTomohiro SaitoTadashi KatoYutaka NakajimaMikio WakasaKanji ShishidoHirokazu HondaPublished in: Clinical journal of the American Society of Nephrology : CJASN (2023)
The BMD of both cortical and trabecular components in the hip region were significantly higher after starting denosumab therapy. However, these measurements exhibited a trend of declining substantially following the discontinuation of denosumab.